[Federal Register Volume 82, Number 207 (Friday, October 27, 2017)]
[Notices]
[Pages 49838-49840]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-23437]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-5896]
Patient-Focused Drug Development: Guidance 1--Collecting
Comprehensive and Representative Input; Public Workshop; Request for
Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing a public
workshop to convene a discussion on methodological approaches that a
person seeking to collect patient experience data for submission to FDA
to inform regulatory decision making may use. The methods and
approaches would be considered relevant and objective, and ensure that
collected data are accurate and representative of the intended
population, including methods to collect meaningful patient input
throughout the drug development process and methodological
considerations for data collection, reporting, management, and
analysis. This workshop will inform development of patient-focused drug
development
[[Page 49839]]
guidance as required by the 21st Century Cures Act (Cures Act), and as
part of commitments made by FDA under the sixth reauthorization of the
Prescription Drug User Fee Act (PDUFA VI). FDA will publish a
discussion document approximately 1 month before the workshop date. FDA
is interested in seeking information and comments on the approaches
proposed in the discussion document. FDA is also interested in input on
examples where the approaches proposed in the discussion document have
been successfully applied that could be illustrated in the draft
guidance.
DATES: The public workshop will be held on December 18, 2017, from 9
a.m. to 5 p.m. Submit either electronic or written comments on this
public workshop by February 16, 2018. See the SUPPLEMENTARY INFORMATION
section for registration date and information.
ADDRESSES: The public workshop will be held at FDA's White Oak Campus,
10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993. Entrance for the public workshop
participants (non-FDA employees) is through Building 1 where routine
security check procedures will be performed. For parking and security
information, please refer to http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
Workshop updates, agenda, and discussion document will be made
available at: https://www.fda.gov/Drugs/NewsEvents/ucm574725.htm prior
to the workshop.
You may submit comments as follows. Please note that late, untimely
filed comments will not be considered. Electronic comments must be
submitted on or before February 16, 2018. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of February 16, 2018. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are postmarked or the delivery
service acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2017-N-5896 for ``Patient-Focused Drug Development: Guidance 1--
Collecting Comprehensive and Representative Input; Public Workshop;
Request for Comments.'' Received comments, those filed in a timely
manner (see ADDRESSES), will be placed in the docket and, except for
those submitted as ``Confidential Submissions,'' publicly viewable at
https://www.regulations.gov or at the Dockets Management Staff between
9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Meghana Chalasani, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 1146, Silver Spring, MD 20993-0002, 240-
402-6525, Fax: 301-847-8443, [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
This public workshop is intended to support FDA implementation of
requirements for guidance development under section 3002 of the Cures
Act and to meet a performance goal included in the sixth
reauthorization of PDUFA VI. This reauthorization, part of the FDA
Reauthorization Act of 2017 (FDARA) signed by the President on August
18, 2017, includes a number of performance goals and procedures that
are documented in the PDUFA VI Commitment Letter, which is available at
https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM511438.pdf.
Section 3002 of Title III, Subtitle A of the Cures Act directs FDA
to develop patient-focused drug development guidance to address a
number of areas including under section 3002(c)(1): Methodological
approaches, which are relevant and objective and ensure that such data
are accurate and representative of the intended population, that a
person seeking to
[[Page 49840]]
collect patient experience data to inform regulatory decision making
may use.
In addition, FDA committed to meet certain performance goals under
PDUFA VI. These goal commitments were developed in consultation with
patient and consumer advocates, health care professionals, and other
public stakeholders, as part of negotiations with regulated industry.
Section J.1 of the commitment letter, ``Enhancing the Incorporation of
the Patient's Voice in Drug Development and Decision-Making,'' (https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM511438.pdf) outlines work, including the development of a series of
guidance documents and associated public workshops to facilitate the
advancement and use of systematic approaches to collect and utilize
robust and meaningful patient and caregiver input that can more
consistently inform drug development, and, as appropriate, regulatory
decision making.
Prior to the issuance of each guidance, as part of the development,
FDA will conduct a public workshop to gather input from the wider
community of patients, patient advocates, academic researchers, expert
practitioners, drug developers, and other stakeholders.
II. Purpose and Scope of Meeting
FDA is announcing a public workshop to convene a discussion on
topics related to approaches to collecting comprehensive and
representative patient and caregiver input on burden of disease and
current therapy. The purpose of this public workshop is to obtain
feedback from stakeholders on considerations for: (1) Standardized
nomenclature and terminologies for patient-focused drug development,
(2) methods to collect meaningful patient input throughout the drug
development process, and (3) methodological considerations for data
collection, reporting, management, and analysis of patient input. FDA
is seeking information and comments from a broad range of stakeholders,
including patients, patient advocates, academic and medical
researchers, expert practitioners, drug developers, and other
interested persons. FDA will publish a discussion document outlining
the topic areas that will be addressed in the draft guidance. This
document will be published approximately 1 month before the workshop
date on the Web site at: https://www.fda.gov/Drugs/NewsEvents/ucm574725.htm. FDA is interested in seeking information and comments on
the approaches and considerations proposed in the discussion document,
as well as the examples provided. FDA is also interested in seeking
information and comments on additional examples where the approaches
proposed in the discussion document have been successfully applied that
could be included in guidance. After this public workshop, FDA will
take into consideration the stakeholder input from the workshop and the
public docket, and publish a draft guidance by the end of the third
quarter of fiscal year 2018.
Registration: Interested parties are encouraged to register early.
To register electronically, please visit: https://pfdd.eventbrite.com.
Persons without access to the internet can call 240-402-6525 to
register. If you are unable to attend the meeting in person, you can
register to view a live webcast of the meeting. You will be asked to
indicate in your registration if you plan to attend in person or via
the webcast. Seating will be limited, so early registration is
recommended. Registration is free and will be on a first-come, first-
served basis. However, FDA may limit the number of participants from
each organization based on space limitations. Registrants will receive
confirmation once they have been accepted. Onsite registration on the
day of the meeting will be based on space availability.
If you need special accommodations because of a disability, please
contact Meghana Chalasani (see FOR FURTHER INFORMATION CONTACT) at
least 7 days before the meeting.
Request for Oral Presentations: There will be time allotted during
the workshop for open public comment. Sign-up for this session will be
on a first-come, first-serve basis on the day of the workshop.
Individuals and organizations with common interests are urged to
consolidate or coordinate, and request time for a joint presentation.
No commercial or promotional material will be permitted to be presented
or distributed at the public workshop.
Transcripts: As soon as a transcript is available, FDA will post it
at https://www.fda.gov/Drugs/NewsEvents/ucm574725.htm.
Dated: October 23, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-23437 Filed 10-26-17; 8:45 am]
BILLING CODE 4164-01-P